Child Neurology Society Symposium Registration
-
Wed., Oct. 8, 2025 | 11:45 AM – 1:45 PM
-
Satellite Symposium, Non-CME
-
W207 ABCD
Session Description: Pediatric neurology is witnessing a paradigm shift in diagnostic evaluation as GS becomes a critical tool for understanding complex neurodevelopmental and neurodegenerative disorders. This Baylor Genetics hosted Satellite Symposium explores the growing impact of GS in pediatric neurology, from its diagnostic utility to its role in informing treatment strategies. Through a multidisciplinary panel of experts, attendees will gain a clear understanding of how GS surpasses traditional testing paradigms, how it’s being integrated as a first-tier diagnostic tool per current guidelines, and how real-world clinical cases, including rare and emerging conditions like ReNU syndrome, underscore the value of comprehensive genomic and transcriptomic approaches. A forward-looking discussion on how positive genomic findings are guiding therapeutic interventions, ultimately enabling precision care in the pediatric neurology landscape will conclude the session.
Join Leah Campbell, MS, CGC, Medical Science Liaison (MSL) at Baylor Genetics; Eileen Barr, MS, CGC, MSL at Baylor Genetics; Andrea Gropman, MD, Director of Neurometabolic Translational Research at St. Jude Children’s Research Hospital; and Chelsea Chambers, CGC, Neurology Genetic Counselor, on Wednesday, October 8, for a compelling Satellite Symposium hosted by Baylor Genetics.
Explore how genome sequencing (GS) is reshaping pediatric neurology by improving diagnostics and guiding treatment. This expert-led session highlights GS as a first-tier tool, its advantages over traditional testing, and real-world cases – including rare conditions like ReNU syndrome. Learn how genomic insights are driving precision care and therapeutic decisions.
Register Below
Genome Sequencing (GS): What Is It and Why It Matters
Speaker: Leah Campbell, MS, CGC
MSL, Baylor Genetics
Time: 11:45 AM – 12:05 PM
Description: An introductory overview of GS, including its technology, clinical breadth, and how it outperforms traditional multi-gene panels and exome sequencing. This session will demystify GS for clinical neurologists and highlight its role as a powerful first-tier test.
Genome Sequencing (GS) in the Neurology Setting: Guidelines and Indications
Speaker: Chelsea Chambers, CGC
Neurology Genetic Counselor
Time: 12:05 PM – 12:25 PM
Description: A clinical deep dive into the most common neurological presentations in children (e.g., epilepsy, hypotonia, developmental delay) and how GS is positioned to reveal molecular diagnoses. The speaker will review key diagnostic guidelines from the American College of Medical Genetics & Genomics (ACMG), American Academy of Pediatrics (AAP), American Epilepsy Society (AES), National Society of Genetics Counselors (NSGC), and other authorities that support the use of GS in neurological care.
Transformative Diagnoses Through Multiomics
Speaker: Eileen Barr, MS, CGC
MSL, Baylor Genetics
Time: 12:25 PM – 12:45 PM
Description: Using powerful case studies, this segment will explore how GS and RNA sequencing have transformed diagnostic odysseys. Special emphasis will be placed on a series of cases, one highlighting a diagnosis of ReNU syndrome (RNU4-2-related neurodegeneration), and others where transcriptomic evidence contributed to diagnosis or enhanced disease understanding.
Therapeutic Pathways After Genomic Diagnosis
Speaker: Dr. Andrea Gropman, MD
Director, Neurometabolic Translational Research, St. Jude Children’s Research Hospital
Time: 12:45 PM – 1:05 PM
Description: Following a positive finding through GS, what’s next? Dr. Gropman will explore how molecular diagnoses lead to actionable therapeutic directions — whether through clinical trials, enzyme replacement, gene-targeted therapies, or dietary/metabolic interventions. Practical examples from neurogenetics clinics will be shared.
Q&A Discussion Panel
Time: 1:05 PM – 1:45 PM
Moderator: Jason Chibuk, MS, CGC
Vice President, Medical Affairs, Baylor Genetics
Description: An open-floor discussion with all speakers, inviting audience questions on implementation, utility, and the future of genomics in neurology.